HOLD-TIME STUDIES.

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Chapter 2 The Process of Experimentation
WHO - PSM Documentation – Part 2 Workshop on GMP and Quality Assurance of TB products Kuala Lumpur Malaysia, 21 – 25 February 2005 Maija Hietava M.Sci.Pharm.
Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Producing a Pharmaceutical or Biopharmaceutical
Annual Product Review (APR) Product Quality Review (PQR)
Stability data required by WHO-PQP Mercy Acquaye.
GMP Document and Record Retention
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Manufacturing Process
Batch Reworking and Reprocessing
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Determine impurity level in relevant batches1
Free Powerpoint Templates Page 1 Mohammad Khalid Anwer, Ph.D - Mohammad Khalid Anwer, Ph.D -
Quality control of raw materials In-process control
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Reference, Retention and Reserve Samples
World Health Organization
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
Codex Guidelines for the Application of HACCP
© 2009 Michigan State University licensed under CC-BY-SA, original at Corrective Action.
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
World Health Organization
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Water | Slide 1 of Water for Pharmaceutical Use Part 3: Operational considerations Supplementary Training Modules on Good Manufacturing Practice.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Quality Assurance D R Rossmann South African National Road Agency Ltd.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Important informations
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Project management Topic 7 Controls. What is a control? Decision making activities – Planning – Monitor progress – Compare achievement with plan – Detect.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
Master Formula And Batch MaNUFACTURING Record
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Module 14Slide 1 of 23 WHO - EDM Basic Principles of GMP Active Pharmaceutical Ingredients Part Three, 18.
Module 12 - part 2Slide 1 of 23 WHO - EDM Basic Principles of GMP Documentation Part 2 Part One, 14.
Spesification of raw material, intermediate and final product Prepared by: Paras Shah Guided by : Dhaval Rathod.
Producing a Pharmaceutical or Biopharmaceutical The Manufacturing Process.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
Quality Control significance in pharmaceutical industry
LABORATORY SAMPLES AND CONTRACT MANAGEMENT
BSB Biomanufacturing CHAPTER 4 GMP – Documentation Part I (SOP)
STABILITY ?.
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
World Health Organization
World Health Organization
Pharmaceutical Quality Control & current Good Manufacturing Practice
Producing a Pharmaceutical or Biopharmaceutical
Author: Nurul Azyyati Sabri
Basic Principles of GMP
Water for Pharmaceutical Use
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
Evaluation of tablet Lab 5.
WHO Technical Report Series, No. 953, 2009
Evaluation of tablet Lab 5.
Food Production Systems
Producing a Pharmaceutical or Biopharmaceutical
World Health Organization
Producing a Pharmaceutical or Biopharmaceutical
Evaluation of tablet Lab 5.
Producing a Pharmaceutical or Biopharmaceutical
Biological Science Applications in Agriculture
Radiopharmaceutical Production
Radiopharmaceutical Production
GL 51 – Statistical evaluation of stability data
Working group on the rule of the 20 %
Presentation transcript:

HOLD-TIME STUDIES

Background Good manufacturing practices (GMP) require that arrangements should be made to ensure that the dispensed raw materials and packaging materials, intermediate products, bulk and finished products are stored under appropriate conditions. Maximum acceptable holding periods should therefore be established to ensure that intermediates and bulk product can be held, pending the next processing step, without producing results outside the acceptance criteria for the quality of the material.

What is Hold Time? Hold time can be considered as the established time period for which materials (dispensed raw materials, intermediates and bulk dosage form awaiting final packaging) may be held under specified conditions and will remain within the defined specifications. Hold-time studies establish the time limits for holding the materials at different stages of production to ensure that the quality of the product does not produce results outside the acceptance criteria during the hold time. The design of the study should reflect the holding time at each stage.

Glossary Bulk product – any pharmaceutical product that has completed all processing stages up to, but not including, final packaging. Intermediate – partly processed product that must undergo further manufacturing steps before it becomes a bulk product.

Objective Manufacturers should gather scientific and justifiable data to demonstrate that the dispensed raw materials and packaging materials, intermediate and bulk products: –– remain of appropriate quality before processing to the next stage; –– meet the acceptance criteria. The finished product should meet the release specifications.

Aspects to be considered Collect data to justify the hold time during: Development on pilot scale batch Process validation As a part of investigation of a deviation that occurred during manufacturing.

Aspects to be considered Manufacturers may use a flow chart to review the manufacturing procedure for a product Break up the critical stages of the manufacturing process on the basis of the time period required for the particular storage and processing stages, typical pauses in the manufacturing campaign, and the potential impact of storage with reference to environmental and storage conditions.

Example of the Flow Chart

Stages to be considered for Coated Tablets Step Product Binder preparation to granulation Granulate Wet granulation to drying Dried granules Dried granules to lubrication/blending Lubricated blend Compression to coating Tablet cores Coating solution to preparation Coating solution Coating to packing Bulk coated tablets

Hold-Time Studies A written protocol, procedure or programme should be followed, which includes, for example, the activities to be performed, test parameters, acceptance criteria appropriate to the material or product under test.

Hold-Time Studies The protocol and report should generally include the following: - a title; reference number; version; date; objective; scope; responsibility; procedure; description of the material or product; sample quantities; sampling method and criteria; acceptance limits; frequency of sampling; sampling locations; pooling of samples; storage conditions; type of container; methods of analysis; results; conclusion; recommendation; signatures; and dates.

Hold-Time Studies Acceptance criteria are typically more stringent than registered specifications, to provide assurance that the material is well within control. When setting the specifications, any known stability trends will need to be taken into account. For certain products, microbiological aspects should also be considered and included where appropriate. All testing of bulk intermediates and product should be performed using validated stability-indicating methods.

Hold-Time Studies Typically one or more batches of a material, intermediate or product can be used for determining hold times. A representative sample of the batch of material or product subjected to the hold-time study should be held for the defined hold period. The hold period for each category of material should be established on the basis of the study by keeping the material in either the original or simulated container used in production. The environmental conditions for sample storage should be the same as those of the quarantine area/manufacture stage.

Hold-Time Studies A sampling plan should be established and followed for taking samples for testing at the different intervals. The amount of sample required should be calculated based on the batch size, the intervals, and the tests to be performed. Results should be compared with the initial baseline data on the control sample.

Hold-Time Studies Batches of finished products made from intermediates or bulk products and subjected to a hold-time study should be considered for long-term stability testing if data show adverse trending or shifting patterns during the intermediate time points up to the end of the shelf-life. The shelf-life of the product – irrespective of hold times – should be measured from the time the active ingredients are mixed with other ingredients. Normally, intermediate and bulk products should not be stored beyond the established hold time.

Stages, study times and tests that may be considered for a coated tablet

Stages, study times and tests that may be considered for a coated tablet

THANK YOU!